优替德隆治疗晚期乳腺癌的临床疗效观察

Clinical Efficacy of Utidelone in the Treatment of Advanced Breast Cancer

目的:探讨优替德隆治疗晚期乳腺恶性肿瘤病人的临床疗效。方法:选取2021年5月至2022年12月就诊于新疆医科大学附属肿瘤医院晚期乳腺癌患者。其中生存分析采用Kaplan-Meier法和Log rank检验,多因素采用Cox回归模型分析。结果:1) 28例患者,5例为部分缓解,16例为疾病稳定,7例为疾病进展,无1例患者达到完全缓解,客观缓解率17.9% (5/28),疾病控制率75% (21/28)。2) 在接受优替德隆的晚期乳腺癌病人中,mPFS为3个月,最高PFS为10个月,中位OS未达到,平均OS为13.4个月。3) 三阴性、Lunminal型、HER-2过表达型乳腺癌的中位PFS分别为4、3和2个月,优替德隆治疗三组患者的疗效无差别(p > 0.05)。结论:优替德隆治疗各种分子亚型的晚期乳腺癌的疗效无差别。优替德隆对于多线化疗失败后的晚期乳腺肿瘤患者具有较好的治疗效果,其具有较好的临床应用价值。

Objective: To explore the clinical efficacy of Utidelone in the treatment of advanced breast cancer patients. Methods: The patients with advanced breast cancer who visited Xinjiang Medical Univer-sity Cancer Hospital from May 2021 to December 2022 were selected. Survival analysis was con-ducted using Kaplan Meier method and Log rank test, while multivariate analysis was conducted using Cox regression model. Result: 1) Of the 28 patients, 5 showed partial response, 16 showed stable disease, 7 showed disease progression, and no patient achieved complete response. The ob-jective response rate was 17.9% (5/28), and the disease control rate was 75% (21/28). 2) Among patients with advanced breast cancer who received Utidelone, the mPFS was 3 months, the highest PFS was 10 months, and the median OS was not achieved, with an average OS of 13.4 months. 3) The median PFS of triple negative, Lunminal, HER-2 overexpression breast cancer was 4, 3, and 2 months, respectively. There was no difference in the efficacy of the three groups of patients treated with Utidelone (p > 0.05). Conclusion: There is no difference in the efficacy of Utidelone in the treatment of various molecular subtypes of advanced breast cancer. Utidelone has a good therapeu-tic effect in patients with advanced breast tumours after failure of multiple lines of chemotherapy, and its clinical application is of good value.